...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of neurosurgery >ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas
【24h】

ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas

机译：ATRX免疫组化可以帮助改进II / III级胶质瘤的分类

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: The 2016 WHO tumour classification highlights the role of IDH1/2 gene mutation and 1p/19q co-deletion in classifying grade II/III gliomas. A recent cIMPACT-NOW update proposes the use of the term 'Not Elsewhere Classified' (NEC) for IDH-mutant, non co-deleted tumours. Here we show how the incorporation of ATRX immunohistochemistry can be used to better delineate the NEC group. Methods: Clinical data was collected for 112 patients (59% male) treated at our unit. Mutations in IDH1/2 genes were detected by pyrosequencing or immunohistochemistry, 1p/19q co-deletion was assessed with fluorescence in situ hybridisation and ATRX status was determined using immunohistochemical techniques. Tumours were grouped on the basis of molecular markers and outcomes compared. Results: The mean age of diagnosis was 42.6 years (20-73 years). There were 88 oligodendrogliomas (II = 47, III = 41), 18 diffuse astrocytomas (II = 9, III = 9) and 6 oligoastrocytomas (II = 4, III = 2). The majority of gliomas (87.5%) had mutations in IDH1/2. 1p/19q co-deletion was significantly associated with oligodendroglial morphology (p = < 0.001) and was mutually exclusive with ATRX mutation. Classification on the basis of molecular information showed a significant different in survival between the groups. Conclusions: ATRX immunohistochemisty is a useful adjunct which can be used with IDH mutation status, 1p/19q co-deletion and histological findings to further define tumour groups. More work is needed to understand the molecular profiles and prognostic implications for non co-deletion, ATRX preserved cases.
机译：目的：2016年肿瘤分类突出了IDH1 / 2基因突变和1P / 19Q共同缺失在分类II / III级胶质瘤中的作用。最近的CIMPACT-NOW更新提出使用术语“不在其他地方”（NEC）（NEC）进行IDH-突变体，非共同缺失的肿瘤。在这里，我们展示了如何使用ATRX免疫组织化学的掺入来更好地描绘NEC组。方法：收集临床资料112名患者（59％男性）在我们的单位治疗。通过焦磷酸或免疫组织化学检测IDH1 / 2基因中的突变，用原位杂交的荧光评估1P / 19Q共缺失，并且使用免疫组化技术测定ATRX状态。基于分子标记和结果进行肿瘤进行分组。结果：平均诊断年龄为42.6岁（20-73岁）。存在88个oligodendrogliomas（II = 47，III = 41），18个弥漫性星形细胞瘤（II = 9，III = 9）和6个oligoSastrocytomas（II = 4，III = 2）。大多数胶质瘤（87.5％）在IDH1 / 2中有突变。 1P / 19Q共缺失与寡突突变形态有显着相关（P = <0.001），并与ATRX突变相互排斥。基于分子信息的分类显示在组之间的存活中显示出显着差异。结论：ATRX免疫组织化学是一种有用的辅助，可用于IDH突变状态，1P / 19Q共缺失和组织学发现，以进一步定义肿瘤群。需要更多的作品来了解分子谱和对非共同缺失的预后影响，ATRX保存的病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号